ClinicalTrials.gg
RecruitingNCT05467111CardioProtExUpdated Apr 11, 2024

Cardioprotective Effect of Acute Exercise in Breast Cancer Patients

An interventional study of Acute Exercise in Early-stage Breast Cancer, sponsored by Technical University of Madrid. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by Technical University of Madrid · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Planned enrollment
690th of 805
40 · median 151
Started
2023
with 59 others
No phase
146 of 905
51 open now
Primary completion
2025-04
later than 54 of 284 live
Registered
684th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 690th largest by planned enrollment of the 805 interventional ones that give a count, is one of 60 that started in 2023, is one of 146 with no phase, reaches primary completion later than 54 of the 284 other live ones, and was the 684th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

Cardiotoxicity is one of the most significant adverse effects in breast cancer patients treated with anthracyclines (a type of chemotherapy), so we propose to determine whether acute training (i.e., 24h before each chemotherapy session) could reduce the levels of a cardiac biomarker which measures muscle damage (NT-proBNP).

Given the fact NT-proBNP attenuation has been observed with one session performed 24h before the first treatment, we propose to verify these findings in each cycle of doxorubicin analyzing how each type of exercise (aerobic, strength or combined aerobic + strength) may impact on anthracycline-induced cardiotoxicity, since this observation may be relevant considering the feasibility and low cost this implementation would represent in clinical practice.

03

Conditions studied

  • Early-stage Breast Cancer

Keywords

  • Breast Cancer
  • Exercise
  • Doxorubicin
  • anthracyclines
  • Cardiotoxicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman with non- breast cancer not previously treated.
  • Scheduled to receive doxorubicin chemotherapy.
  • Receive the oncologist´s approval for the practice of exercise.
  • Acceptance of randomization.
  • To sign an form before starting any measurement or procedure related to the project.

Exclusion criteria

Exclusion Criteria:

  • Patients who receive initial surgery and who are not going to receive treatment.
  • to perform stress tests following the recommendations of the American Thoracic Society.
  • Pre-existing cardiovascular disease.
  • (BMI) > 35 kg/m2.
  • Diabetes mellitus.
  • Renal disease.
  • Severe anemia.
  • Pregnacy.
  • Current smoking status.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Exercise

    Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines) 24-48 hours prior to each cycle of anthracyclines.

    Other: Acute Exercise

  • No intervention
    Control

    Patients will receive standard treatment for each type of tumor proposed by the hospital. This group of patients will be provided with the international recommendations on physical exercise for cancer patients.

Interventions

  • OtherAcute Exercise

    Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.

06

What researchers measure

Primary outcomes

  1. NT-proBNP

    Biomarker of cardiac injury value in blood tests

    Time frame: 24-48 hours prior to each cycle of anthracyclines and immediately prior to receiving the treatment

Secondary outcomes

  1. Cardiac Troponin I

    Biomarker of cardiac injury value in blood tests

    Time frame: 24-48 hours prior to each cycle of anthracyclines and immediately prior to receiving the treatment

  2. Blood Pressure

    Resting blood pressure assesed by sphyngomanometer

    Time frame: 24-48 hours prior to each cycle of anthracyclines and immediately prior to receiving the treatment

  3. Left Ventricular Ejection Fraction (LVEF)

    Change in left ventricular systolic function quantified by transthoracic echocardiography

    Time frame: 0-14 days prior to the first treatment ( according to the usual clinical practice) and in the follow-up period (6 months after completion of the anthracycline treatment).

Other outcomes

  1. Changes in Quality of Life

    Assesed using the validated EORTC-QLQ-C30 quality of life questionnaire

    Time frame: Prior to each exercise session and in the follow-up period (6 months after completion of the anthracycline treatment).

  2. Fatigue

    Assesed using the validated Functional Assessment of Cancer Therapy: Fatigue (FACT-F)

    Time frame: Prior to each exercise session and in the follow-up period (6 months after completion of the anthracycline treatment).

  3. Physical Activity

    Assesed using the validated International Physical Activity Questionnaire (IPAQ-SF)

    Time frame: Prior to each exercise session and in the follow-up period (6 months after completion of the anthracycline treatment).

  4. Assessment of functional mobility

    Assesed using the Timed Up and Go (TUG) test

    Time frame: 0-14 days prior to the first treatment and immediately after completion of the anthracycline treatment.

  5. Assessment of lower extremity strength and power

    Assesed using the Sit to Stand test

    Time frame: 0-14 days prior to the first treatment and immediately after completion of the anthracycline treatment.

  6. Assessment of isometric handgrip

    Assesed using the hand grip dynamometer test

    Time frame: 0-14 days prior to the first treatment and immediately after completion of the anthracycline treatment.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Apr 2025, 27 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 27 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2022
First posted
Jul 20, 2022
StartActual
Jan 23, 2023
Primary completionEst.
Apr 2025
CompletionEst.
Oct 2025
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05467111
Lead sponsor
Technical University of Madrid
Responsible party
Alejandro San Juan Ferrer (PhD Physical Activity and Health, Technical University of Madrid) — Principal investigator
First posted
Jul 20, 2022
Start date
Jan 23, 2023
Primary completion
Apr 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Apr 11, 2024

Study contacts

María Alonso
Contact
maria.alonsod@alumnos.upm.es
+ 34 678942096

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion